Warning letterPosted May 19, 2026
FDA warning letter to Hangzhou Yiqi Biotechnology Co., Ltd
CGMP/Active Pharmaceutical Ingredient (API)/Adulterated
FDA posted a warning letter to Hangzhou Yiqi Biotechnology Co., Ltd on May 19, 2026; the letter is dated April 15, 2026. Subject: CGMP/Active Pharmaceutical Ingredient (API)/Adulterated. Issuing office: Center for Drug Evaluation and Research (CDER).
On the record
- Company
- Hangzhou Yiqi Biotechnology Co., Ltd
- Subject
- CGMP/Active Pharmaceutical Ingredient (API)/Adulterated
- Issuing office
- Center for Drug Evaluation and Research (CDER)
- Letter dated
- 2026-04-15
- Posted by FDA
- 2026-05-19
- Source
- FDA warning letters ↗
The full record
An account shows the violations FDA described and each CFR section it cited.
What a warning letter is
A warning letter is FDA's notice to a company that it found significant violations of federal requirements. FDA asks for a written response, normally within 15 working days. The letter is advisory: it states the agency's position and is not a final agency action.
More
Watch Hangzhou Yiqi Biotechnology Co., Ltd
A free account shows the last 7 days of every record. Pro adds a watchlist: one email when FDA acts on a company you name.
From FDA warning letters. The record may have changed since it was read.
Approve Suite is not affiliated with FDA, or with Hangzhou Yiqi Biotechnology Co., Ltd.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.